RxDoctor Payments Data

Matthew McConnell, MD

Neurology · Greenwich, CTNPI 1699018044

Payments from drug & device makers

$15,192in general payments, 2019–2025

Across 917 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$2K
  • Novartis$932
  • AbbVie$839
  • Biohaven Pharmaceuticals, Inc.$760
  • Nevro Corp.$708
  • Eisai Inc.$632
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$1591%
  • Travel & lodging$1391%
  • Food & beverage$14,74197%
  • Education$1521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.111$1,586
Novartis65$932
AbbVie(2 entities)73$839
Biohaven Pharmaceuticals, Inc.50$760
Nevro Corp.6$708
Eisai Inc.34$632
MDD US Operations, LLC41$584
Livanova USA, Inc.15$526
Biohaven Pharmaceutical Holding Company Ltd.30$469
Takeda Pharmaceuticals U.S.A., Inc.26$452
Lilly USA, LLC32$451
Sunovion Pharmaceuticals Inc.26$429
Biogen24$420
Greenwich Biosciences, Inc.50$415
Avanir Pharmaceuticals, Inc.25$401
Impel Pharmaceuticals Inc.27$369
Neurelis, Inc.19$335
UCB, Inc.16$326
Amgen(2 entities)12$324
Supernus Pharmaceuticals, Inc.22$283
Sanofi14$281
EMD Serono, Inc.16$274
AstraZeneca13$241
Pfizer11$193
Acadia Pharmaceuticals Inc16$190
Assertio Therapeutics, Inc.9$166
Mallinckrodt Hospital Products Inc.8$163
Bristol Myers Squibb9$160
Johnson & Johnson8$149
Bausch Health US, LLC9$142
Aquestive Therapeutics, Inc.8$136
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)1$135
Lundbeck LLC7$130
Upsher-smith Laboratories LLC7$127
Amneal Pharmaceuticals LLC1$125
Arbor Pharmaceuticals, Inc.7$121
SK Life Science, Inc.7$121
Adamas Pharmaceuticals, Inc.7$120
Jazz Pharmaceuticals Inc.6$119
Collegium Pharmaceutical, Inc.4$75
Shire North American Group Inc5$70
Ironshore Pharmaceuticals Inc.4$67
Banner Life Sciences, LLC3$58
Sumitomo Pharma America, Inc.3$58
Acorda Therapeutics, Inc2$47
E.r. Squibb & Sons, L.L.C.2$45
Almatica Pharma LLC2$44
Zyla Life Sciences, Inc.3$42
Grifols USA, LLC2$40
Neurocrine Biosciences, Inc.2$32
Zogenix Inc.2$27
Avion Pharmaceuticals1$23
Alnylam Pharmaceuticals Inc.1$23
Corium, LLC2$23
Xeris Pharmaceuticals, Inc.1$22
GE HealthCare1$21
Aprecia Pharmaceuticals, LLC1$20
Akcea Therapeutics, Inc.1$19
Harmony Biosciences LLC1$17
Mallinckrodt Enterprises LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,192 in reported general payments places this provider in the 70th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$43,140
Medicare patients
219
Services billed
358

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate52$98,941
UbrelvyUbrogepant45$66,267
Aimovig AutoinjectorErenumab-Aooe49$63,485
NuedextaDextromethorphan Hbr/Quinidine18$32,834
BriviactBrivaracetam16$24,449
NayzilamMidazolam22$19,430
Ajovy AutoinjectorFremanezumab-Vfrm16$14,570
Emgality PenGalcanezumab-Gnlm12$8,232
Carbamazepine ErCarbamazepine22$3,651
Lacosamide36$3,646
Sumatriptan Succinate40$3,362
Memantine Hcl130$3,165
Gabapentin127$3,130
Oxcarbazepine27$2,757
Levetiracetam41$2,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$193$98,94152 claims
AbbVieUbrelvy$839$66,26745 claims
UCB, Inc.Briviact, Nayzilam$326$43,88038 claims
Avanir Pharmaceuticals, Inc.Nuedexta$401$32,83418 claims
Upsher-smith Laboratories LLCTopiramate$127$53358 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 280 neurology providers in Connecticut.

Other neurology in Greenwich

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →